Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge
Oliver Sartor, MD
Advertisement
Articles by Oliver Sartor, MD
Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Radium-223 in Early Prostate Cancer
Dr. Oliver Sartor, from Tulane Cancer Center, Describes Patients in the ALSYMPCA Radium-223 Trial
Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations
Dr. Oliver Sartor from Tulane Cancer Center Discusses the Novel Agent Radium-223
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
5